{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:38:51Z","timestamp":1784803131404,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Fundamental Research Funds for the Central Universities, Sun Yat-sen University","award":["24qnpy187"],"award-info":[{"award-number":["24qnpy187"]}]},{"name":"The Fundamental Research Funds for the Central Universities, Sun Yat-sen University","award":["24xkjc021"],"award-info":[{"award-number":["24xkjc021"]}]},{"name":"Shenzhen Science and Technology Program","award":["KQTD20190929173853397"],"award-info":[{"award-number":["KQTD20190929173853397"]}]},{"name":"The \"Pearl River Talent Plan\" Innovation and Entrepreneurship Team Project of Guangdong Province","award":["2019ZT08Y464"],"award-info":[{"award-number":["2019ZT08Y464"]}]},{"name":"The Guangdong Basic and Applied Basic Research Foundation","award":["2022B1515120085"],"award-info":[{"award-number":["2022B1515120085"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03995-4","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T14:30:33Z","timestamp":1742394633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A novel peptide targeting CCR7 inhibits tumor cell lymph node metastasis"],"prefix":"10.1007","volume":"74","author":[{"given":"Yixuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoming","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuman","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"3995_CR1","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2023.01.002","volume":"18","author":"Y Li","year":"2023","unstructured":"Li Y, Byun AJ, Choe JK et al (2023) Micropapillary and solid histologic patterns in N1 and N2 lymph node metastases are independent factors of poor prognosis in patients with stages II to III lung adenocarcinoma. J Thorac Oncol 18:608\u2013619. https:\/\/doi.org\/10.1016\/j.jtho.2023.01.002","journal-title":"J Thorac Oncol"},{"key":"3995_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijsu.2016.08.528","volume":"37","author":"E Al-Sukhni","year":"2017","unstructured":"Al-Sukhni E, Attwood K, Gabriel EM, LeVea CM, Kanehira K, Nurkin SJ (2017) Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. Int J Surg 37:42\u201349. https:\/\/doi.org\/10.1016\/j.ijsu.2016.08.528","journal-title":"Int J Surg"},{"key":"3995_CR3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/ni.3492","volume":"17","author":"A Riedel","year":"2016","unstructured":"Riedel A, Shorthouse D, Haas L, Hall BA, Shields J (2016) Tumor-induced stromal reprogramming drives lymph node transformation. Nat Immunol 17:1118\u20131127. https:\/\/doi.org\/10.1038\/ni.3492","journal-title":"Nat Immunol"},{"key":"3995_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.cell.2022.04.019","volume":"185","author":"NE Reticker-Flynn","year":"2022","unstructured":"Reticker-Flynn NE, Zhang W, Belk JA et al (2022) Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185:1924\u201342.e23. https:\/\/doi.org\/10.1016\/j.cell.2022.04.019","journal-title":"Cell"},{"key":"3995_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","volume":"585","author":"JM Ubellacker","year":"2020","unstructured":"Ubellacker JM, Tasdogan A, Ramesh V et al (2020) Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585:113\u2013118. https:\/\/doi.org\/10.1038\/s41586-020-2623-z","journal-title":"Nature"},{"key":"3995_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2020.02.015","volume":"483","author":"Y Su","year":"2020","unstructured":"Su Y, Zhao B, Zhou L, Zhang Z, Shen Y, Lv H, AlQudsy LHH, Shang P (2020) Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett 483:127\u2013136. https:\/\/doi.org\/10.1016\/j.canlet.2020.02.015","journal-title":"Cancer Lett"},{"key":"3995_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/cac2.12295","volume":"42","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Singh M et al (2022) Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun (Lond) 42:689\u2013715. https:\/\/doi.org\/10.1002\/cac2.12295","journal-title":"Cancer Commun (Lond)"},{"key":"3995_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.immuni.2010.04.017","volume":"32","author":"K Schumann","year":"2010","unstructured":"Schumann K, L\u00e4mmermann T, Bruckner M et al (2010) Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells. Immunity 32:703\u2013713. https:\/\/doi.org\/10.1016\/j.immuni.2010.04.017","journal-title":"Immunity"},{"key":"3995_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1158\/2326-6066.Cir-18-0651","volume":"7","author":"CM Cristiani","year":"2019","unstructured":"Cristiani CM, Turdo A, Ventura V et al (2019) Accumulation of circulating CCR7(+) natural killer cells marks melanoma evolution and reveals a CCL19-dependent metastatic pathway. Cancer Immunol Res 7:841\u2013852. https:\/\/doi.org\/10.1158\/2326-6066.Cir-18-0651","journal-title":"Cancer Immunol Res"},{"key":"3995_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1369\/0022155418824274","volume":"67","author":"X Jiao","year":"2019","unstructured":"Jiao X, Shu G, Liu H et al (2019) The diagnostic value of chemokine\/chemokine receptor pairs in hepatocellular carcinoma and colorectal liver metastasis. J Histochem Cytochem 67:299\u2013308. https:\/\/doi.org\/10.1369\/0022155418824274","journal-title":"J Histochem Cytochem"},{"key":"3995_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12943-015-0306-4","volume":"14","author":"E Tutunea-Fatan","year":"2015","unstructured":"Tutunea-Fatan E, Majumder M, Xin X, Lala PK (2015) The role of CCL21\/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis. Mol Cancer 14:35. https:\/\/doi.org\/10.1186\/s12943-015-0306-4","journal-title":"Mol Cancer"},{"key":"3995_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13046-015-0268-9","volume":"34","author":"M Shi","year":"2015","unstructured":"Shi M, Chen D, Yang D, Liu XY (2015) CCL21-CCR7 promotes the lymph node metastasis of esophageal squamous cell carcinoma by up-regulating MUC1. J Exp Clin Cancer Res 34:149. https:\/\/doi.org\/10.1186\/s13046-015-0268-9","journal-title":"J Exp Clin Cancer Res"},{"key":"3995_CR13","doi-asserted-by":"publisher","first-page":"188499","DOI":"10.1016\/j.bbcan.2020.188499","volume":"1875","author":"A Salem","year":"2021","unstructured":"Salem A, Alotaibi M, Mroueh R, Basheer HA, Afarinkia K (2021) CCR7 as a therapeutic target in Cancer. Biochim Biophys Acta Rev Cancer 1875:188499. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188499","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3995_CR14","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.7150\/ijbs.67138","volume":"18","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhu L, Yao X et al (2022) Paclitaxel treatment enhances lymphatic metastasis of B16F10 melanoma cells via CCL21\/CCR7 axis. Int J Biol Sci 18:1476\u20131490. https:\/\/doi.org\/10.7150\/ijbs.67138","journal-title":"Int J Biol Sci"},{"key":"3995_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/abbs\/gmy077","volume":"50","author":"J Wu","year":"2018","unstructured":"Wu J, Li L, Liu J et al (2018) CC chemokine receptor 7 promotes triple-negative breast cancer growth and metastasis. Acta Biochim Biophys Sin (Shanghai) 50:835\u2013842. https:\/\/doi.org\/10.1093\/abbs\/gmy077","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"3995_CR16","doi-asserted-by":"publisher","first-page":"11802","DOI":"10.1158\/0008-5472.Can-06-1222","volume":"66","author":"JL Wilson","year":"2006","unstructured":"Wilson JL, Burchell J, Grimshaw MJ (2006) Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 66:11802\u201311807. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-1222","journal-title":"Cancer Res"},{"key":"3995_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4161\/cbt.7.7.6065","volume":"7","author":"S Yu","year":"2008","unstructured":"Yu S, Duan J, Zhou Z, Pang Q, Wuyang J, Liu T, He X, Xinfa L, Chen Y (2008) A critical role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in vitro and in vivo. Cancer Biol Ther 7:1037\u20131043. https:\/\/doi.org\/10.4161\/cbt.7.7.6065","journal-title":"Cancer Biol Ther"},{"key":"3995_CR18","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.cell.2019.07.028","volume":"178","author":"K Jaeger","year":"2019","unstructured":"Jaeger K, Bruenle S, Weinert T et al (2019) Structural basis for allosteric ligand recognition in the human CC chemokine receptor 7. Cell 178:1222\u201330.e10. https:\/\/doi.org\/10.1016\/j.cell.2019.07.028","journal-title":"Cell"},{"key":"3995_CR19","doi-asserted-by":"publisher","first-page":"e1805182","DOI":"10.1002\/smll.201805182","volume":"15","author":"S An","year":"2019","unstructured":"An S, Tiruthani K, Wang Y et al (2019) Locally trapping the C-C chemokine receptor type 7 by gene delivery nanoparticle inhibits lymphatic metastasis prior to tumor resection. Small 15:e1805182. https:\/\/doi.org\/10.1002\/smll.201805182","journal-title":"Small"},{"key":"3995_CR20","doi-asserted-by":"publisher","first-page":"1917484","DOI":"10.1080\/19420862.2021.1917484","volume":"13","author":"C Cuesta-Mateos","year":"2021","unstructured":"Cuesta-Mateos C, Ju\u00e1rez-S\u00e1nchez R, Mateu-Albero T, Loscertales J, Mol W, Terr\u00f3n F, Mu\u00f1oz-Calleja C (2021) Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL. MAbs 13:1917484. https:\/\/doi.org\/10.1080\/19420862.2021.1917484","journal-title":"MAbs"},{"key":"3995_CR21","doi-asserted-by":"publisher","first-page":"106343","DOI":"10.1016\/j.phrs.2022.106343","volume":"182","author":"L Jiao","year":"2022","unstructured":"Jiao L, Dong Q, Zhai W, Zhao W, Shi P, Wu Y, Zhou X, Gao Y (2022) A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy. Pharmacol Res 182:106343. https:\/\/doi.org\/10.1016\/j.phrs.2022.106343","journal-title":"Pharmacol Res"},{"key":"3995_CR22","doi-asserted-by":"publisher","first-page":"15114","DOI":"10.1002\/anie.202002783","volume":"59","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zuo C, Li W et al (2020) A novel d-peptide identified by mirror-image phage display blocks TIGIT\/PVR for cancer immunotherapy. Angew Chem Int Ed Engl 59:15114\u201315118. https:\/\/doi.org\/10.1002\/anie.202002783","journal-title":"Angew Chem Int Ed Engl"},{"key":"3995_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000905","author":"H Wang","year":"2020","unstructured":"Wang H, Sun Y, Zhou X et al (2020) CD47\/SIRP\u03b1 blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000905","journal-title":"J Immunother Cancer"},{"key":"3995_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.tips.2010.06.003","volume":"31","author":"K Bellmann-Sickert","year":"2010","unstructured":"Bellmann-Sickert K, Beck-Sickinger AG (2010) Peptide drugs to target G protein-coupled receptors. Trends Pharmacol Sci 31:434\u2013441. https:\/\/doi.org\/10.1016\/j.tips.2010.06.003","journal-title":"Trends Pharmacol Sci"},{"key":"3995_CR25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","volume":"26","author":"B Bockorny","year":"2020","unstructured":"Bockorny B, Semenisty V, Macarulla T et al (2020) BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med 26:878\u2013885. https:\/\/doi.org\/10.1038\/s41591-020-0880-x","journal-title":"Nat Med"},{"key":"3995_CR26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/cncr.33338","volume":"127","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Ofran Y, Tallman MS et al (2021) BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed\/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study. Cancer 127:1246\u20131259. https:\/\/doi.org\/10.1002\/cncr.33338","journal-title":"Cancer"},{"key":"3995_CR27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10637-020-01058-2","volume":"39","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Atkins MB, Rose TL et al (2021) A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Invest New Drugs 39:1019\u20131027. https:\/\/doi.org\/10.1007\/s10637-020-01058-2","journal-title":"Invest New Drugs"},{"key":"3995_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.apsb.2023.12.011","volume":"14","author":"Y Qian","year":"2024","unstructured":"Qian Y, Sun Y, Shi P et al (2024) Development of LAG-3\/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy. Acta Pharm Sin B 14:1150\u20131165. https:\/\/doi.org\/10.1016\/j.apsb.2023.12.011","journal-title":"Acta Pharm Sin B"},{"key":"3995_CR29","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1002\/ctm2.497","volume":"11","author":"H Zheng","year":"2021","unstructured":"Zheng H, Chen C, Luo Y et al (2021) Tumor-derived exosomal BCYRN1 activates WNT5A\/VEGF-C\/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer. Clin Transl Med 11:e497. https:\/\/doi.org\/10.1002\/ctm2.497","journal-title":"Clin Transl Med"},{"key":"3995_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1182\/blood-2016-05-702738","volume":"129","author":"D Askew","year":"2017","unstructured":"Askew D, Pareek TK, Eid S, Ganguly S, Tyler M, Huang AY, Letterio JJ, Cooke KR (2017) Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice. Blood 129:246\u2013256. https:\/\/doi.org\/10.1182\/blood-2016-05-702738","journal-title":"Blood"},{"key":"3995_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3892\/ijo.2017.4003","volume":"51","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, Huang F, Li X, Chen Z, Feng D, Jiang H, Chen W, Zhang X (2017) CCL21\/CCR7 interaction promotes cellular migration and invasion via modulation of the MEK\/ERK1\/2 signaling pathway and correlates with lymphatic metastatic spread and poor prognosis in urinary bladder cancer. Int J Oncol 51:75\u201390. https:\/\/doi.org\/10.3892\/ijo.2017.4003","journal-title":"Int J Oncol"},{"key":"3995_CR32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/nature08020","volume":"459","author":"S Buonamici","year":"2009","unstructured":"Buonamici S, Trimarchi T, Ruocco MG et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459:1000\u20131004. https:\/\/doi.org\/10.1038\/nature08020","journal-title":"Nature"},{"key":"3995_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ccell.2022.07.001","volume":"40","author":"HL Chan","year":"2022","unstructured":"Chan HL, Zhang XH (2022) Node foretold: cancer cells in lymph node rewire the immune system to enable further metastases. Cancer Cell 40:812\u2013814. https:\/\/doi.org\/10.1016\/j.ccell.2022.07.001","journal-title":"Cancer Cell"},{"key":"3995_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00262-021-03014-2","volume":"71","author":"T Mateu-Albero","year":"2022","unstructured":"Mateu-Albero T, Ju\u00e1rez-S\u00e1nchez R, Loscertales J, Mol W, Terr\u00f3n F, Mu\u00f1oz-Calleja C, Cuesta-Mateos C (2022) Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. Cancer Immunol Immunother 71:627\u2013636. https:\/\/doi.org\/10.1007\/s00262-021-03014-2","journal-title":"Cancer Immunol Immunother"},{"key":"3995_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1756-8722-6-89","volume":"6","author":"B Somovilla-Crespo","year":"2013","unstructured":"Somovilla-Crespo B, Alfonso-P\u00e9rez M, Cuesta-Mateos C et al (2013) Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma. J Hematol Oncol 6:89. https:\/\/doi.org\/10.1186\/1756-8722-6-89","journal-title":"J Hematol Oncol"},{"key":"3995_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40364-020-00234-z","volume":"8","author":"C Cuesta-Mateos","year":"2020","unstructured":"Cuesta-Mateos C, Fuentes P, Schrader A et al (2020) CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia. Biomark Res 8:54. https:\/\/doi.org\/10.1186\/s40364-020-00234-z","journal-title":"Biomark Res"},{"key":"3995_CR37","doi-asserted-by":"publisher","first-page":"11656","DOI":"10.1074\/jbc.M111.310045","volume":"287","author":"LA Shannon","year":"2012","unstructured":"Shannon LA, McBurney TM, Wells MA, Roth ME, Calloway PA, Bill CA, Islam S, Vines CM (2012) CCR7\/CCL19 controls expression of EDG-1 in T cells. J Biol Chem 287:11656\u201311664. https:\/\/doi.org\/10.1074\/jbc.M111.310045","journal-title":"J Biol Chem"},{"key":"3995_CR38","doi-asserted-by":"publisher","first-page":"23214","DOI":"10.1074\/jbc.M402125200","volume":"279","author":"TA Kohout","year":"2004","unstructured":"Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS (2004) Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1\/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem 279:23214\u201323222. https:\/\/doi.org\/10.1074\/jbc.M402125200","journal-title":"J Biol Chem"},{"key":"3995_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nri2297","volume":"8","author":"R F\u00f6rster","year":"2008","unstructured":"F\u00f6rster R, Davalos-Misslitz AC, Rot A (2008) CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 8:362\u2013371. https:\/\/doi.org\/10.1038\/nri2297","journal-title":"Nat Rev Immunol"},{"key":"3995_CR40","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nm.3709","volume":"20","author":"MR Clatworthy","year":"2014","unstructured":"Clatworthy MR, Aronin CE, Mathews RJ, Morgan NY, Smith KG, Germain RN (2014) Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat Med 20:1458\u20131463. https:\/\/doi.org\/10.1038\/nm.3709","journal-title":"Nat Med"},{"key":"3995_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1126\/science.aav0173","volume":"363","author":"CK Lee","year":"2019","unstructured":"Lee CK, Jeong SH, Jang C, Bae H, Kim YH, Park I, Kim SK, Koh GY (2019) Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science 363:644\u2013649. https:\/\/doi.org\/10.1126\/science.aav0173","journal-title":"Science"},{"key":"3995_CR42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41590-024-01856-3","volume":"25","author":"Z Alraies","year":"2024","unstructured":"Alraies Z, Rivera CA, Delgado MG et al (2024) Cell shape sensing licenses dendritic cells for homeostatic migration to lymph nodes. Nat Immunol 25:1193\u20131206. https:\/\/doi.org\/10.1038\/s41590-024-01856-3","journal-title":"Nat Immunol"},{"key":"3995_CR43","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/s41423-021-00726-4","volume":"18","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang X, Cheng Y, Cao X (2021) Dendritic cell migration in inflammation and immunity. Cell Mol Immunol 18:2461\u20132471. https:\/\/doi.org\/10.1038\/s41423-021-00726-4","journal-title":"Cell Mol Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03995-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03995-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03995-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:48:50Z","timestamp":1745750930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03995-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["3995"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03995-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"153"}}